Hemostatic Effects of Tranexamic Acid in Cesarean Delivery: An Ancillary Study of the TRAAP2 Study.
| dc.rights.license | open | en_US |
| hal.structure.identifier | Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases | |
| dc.contributor.author | ROULLET, Stéphanie | |
| hal.structure.identifier | CHU Bordeaux | |
| dc.contributor.author | RIVOIRE, Timothée | |
| hal.structure.identifier | Centre Hospitalier Universitaire de Bordeaux [CHU de Bordeaux] | |
| dc.contributor.author | HOUSSIN, Clémence | |
| hal.structure.identifier | Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases | |
| dc.contributor.author | LABROUCHE, Sylvie | |
| hal.structure.identifier | Centre Hospitalier Universitaire de Bordeaux [CHU de Bordeaux] | |
| dc.contributor.author | PAQUIN, Sandrine | |
| hal.structure.identifier | Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM] | |
| dc.contributor.author | NOUETTE-GAULAIN, Karine | |
| dc.contributor.author | DENEUX-THARAUX, Catherine | |
| dc.contributor.author | AMIRAL, Jean | |
| hal.structure.identifier | Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases | |
| dc.contributor.author | JAMES, Chloé | |
| hal.structure.identifier | Centre Hospitalier Universitaire de Bordeaux [CHU de Bordeaux] | |
| dc.contributor.author | SENTILHES, Loïc | |
| dc.date.accessioned | 2023-03-03T11:57:41Z | |
| dc.date.available | 2023-03-03T11:57:41Z | |
| dc.date.issued | 2022-11-01 | |
| dc.identifier.issn | 2567-689X | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/172156 | |
| dc.description.abstractEn | Fibrinolysis activation during delivery contributes to postpartum hemorrhage (PPH). Clot lysis time studied with the global fibrinolytic capacity device (GFC/LT) is a functional test which rapidly assesses fibrinolytic profile. Tranexamic acid (TXA) is an efficient antifibrinolytic therapy. We prospectively studied fibrinolysis and coagulation in 33 women included in the TRAAP2 trial, which aimed to assess the impact of TXA in preventing PPH following a cesarean delivery. TXA or placebo was randomly administered after childbirth as part of the TRAAP2 trial's protocol. Fibrinolytic (GFC/LT, plasma concentration of fibrinolysis activators and inhibitors) and hemostatic parameters were assayed at three sample times (TREF [T-reference] after anesthesia, T15 and T120minutes after TXA, or placebo administration). All cesarean deliveries were elective. In the placebo group, the clot lysis time assessed with GFC/LT significantly decreased between TREF and T120, indicating an activated fibrinolysis (44 [interquartile range, IQR: 40-48] vs. 34 [IQR: 30-36] minutes, <0.001). In both TXA and placebo groups, significant fluctuations of the plasmatic concentrations of fibrinolytic mediators were noticed over time, suggesting fibrinolysis activation. Clot lysis time measured by GFC/LT was significantly increased in women of the TXA group as compared with those in the placebo group at T15 (120 [120-120] vs. 36 [34-41] minutes, <0.001) and T120minutes (113 [99-120] vs. 34 [30-36] minutes, <0.001) after drug administration, indicating a decreased in fibrinolysis in those women. GFC/LT evidenced fibrinolysis activation during cesarean delivery, linked to a decrease in fibrinolytic inhibitors. GFC/LT revealed a significant antifibrinolytic effect of TXA compared with placebo. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Female | |
| dc.subject.en | Humans | |
| dc.subject.en | Pregnancy | |
| dc.subject.en | Antifibrinolytic Agents | |
| dc.subject.en | Fibrin Clot Lysis Time | |
| dc.subject.en | Fibrinolysis | |
| dc.subject.en | Hemostatics | |
| dc.subject.en | Postpartum Hemorrhage | |
| dc.subject.en | Tranexamic Acid | |
| dc.title.en | Hemostatic Effects of Tranexamic Acid in Cesarean Delivery: An Ancillary Study of the TRAAP2 Study. | |
| dc.title.alternative | Thromb Haemost | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1055/s-0042-1755379 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Médecine humaine et pathologie | en_US |
| dc.identifier.pubmed | 36075235 | en_US |
| bordeaux.journal | Thrombosis and Haemostasis | en_US |
| bordeaux.page | 1869-1878 | en_US |
| bordeaux.volume | 122 | en_US |
| bordeaux.hal.laboratories | Biologie des maladies cardiovasculaires (BMC) - UMR 1034 | en_US |
| bordeaux.issue | 11 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | pubmed | |
| hal.identifier | hal-04013288 | |
| hal.version | 1 | |
| hal.date.transferred | 2023-03-03T11:57:44Z | |
| hal.export | true | |
| workflow.import.source | pubmed | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Thrombosis%20and%20Haemostasis&rft.date=2022-11-01&rft.volume=122&rft.issue=11&rft.spage=1869-1878&rft.epage=1869-1878&rft.eissn=2567-689X&rft.issn=2567-689X&rft.au=ROULLET,%20St%C3%A9phanie&RIVOIRE,%20Timoth%C3%A9e&HOUSSIN,%20Cl%C3%A9mence&LABROUCHE,%20Sylvie&PAQUIN,%20Sandrine&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||